Venture Partner
Thuja CapitalCheck size: Thuja Capital does not publish a standard check-size range on its current official site.
Michel de Baar invests or supports investment decisions through Thuja Capital's published strategy: Back European biotech and medtech founders translating scientific breakthroughs into products that can reach patients and improve healthcare.
Strong science, differentiated intellectual property, experienced teams and a credible path from laboratory validation to clinical and commercial impact.
The published strategy centers on European early-stage biotech and medtech; opportunities outside life sciences or without defensible science are less aligned.
Show the unmet need, scientific evidence, IP position, development and regulatory plan, team capability, capital requirements and path to patient impact.
No writing has been linked yet. Kit can search for posts, interviews, and fund essays worth reading before outreach.
No podcast appearances are linked yet. Ask Kit to check for interviews that reveal how this investor thinks.
Quote coverage is incomplete. Kit can look for direct comments on markets, founders, and investment criteria.
Michel de Baar is a current Venture Partner at Thuja Capital, according to the firm's official roster. No education, prior employment or personal deal claims are inferred where the firm does not publish them.